HIM
VRTX icon

Hotaling Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hotaling Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.79M Buy
6,195
+26
+0.4% +$7.92K 0.81% 36
2022
Q3 		$1.79M Sell
6,169
-53
-0.9% -$15.2K 0.86% 36
2022
Q2 		$1.75M Buy
+6,222
New +$1.67M 0.76% 40

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hotaling Investment Management's VRTX Position: Q4 2022 in Review

Hotaling Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.42% in Q4 2022, buying an estimated $7.92K and bringing the position to 6,195 shares worth $1.79M. The position accounts for 0.81% of the portfolio, ranked #36.

Hotaling Investment Management first reported a position in VRTX in Q2 2022 and has held it in 3 quarters since. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Hotaling Investment Management held 6,195 shares of Vertex Pharmaceuticals worth $1.79M as of Q4 2022.
  • Hotaling Investment Management bought 26 Vertex Pharmaceuticals shares in Q4 2022, an estimated $7.92K.
  • Vertex Pharmaceuticals made up 0.81% of Hotaling Investment Management's portfolio in Q4 2022, its #36 holding.
  • Hotaling Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Hotaling Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.